Clinical Trial Update: Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections [Phase 3]

View source ↗

Summary

Phase 3 trial update on ceftobiprole for resistant Staphylococcus aureus skin and skin structure infections; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcal Skin and Skin Structure Infections

Drugs mentioned

• ceftobiprole (ceftobiprole)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 3 | Status: COMPLETED